Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00214604
Status:
COMPLETED
Last Update Posted:
2010-11-19
First Post:
2005-09-21
Brief Title:
Type III Dysbetalipoproteinemia
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An 18-week Randomized Multicenter Phase 3b Double-blind Crossover Study Followed by an 18-week Open-Label Period to Evaluate the Efficacy Safety of the Lipid-Regulating Agents Rosuvastatin Pravastatin in the Treatment of Subjects With Dysbetalipoproteinemia Frederickson Type III Hyperlipoproteinemia
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluation of the efficacy of rosuvastatin 10mg rosuvastatin 20mg and pravastatin 40mg in subjects with dysbetalipoproteinemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None